Case report

Splenic infarction as a rare presentation of severe babesiosis

Arsalan Alvi\(^a\), Sonali Gupta\(^a, b\), Pradeep Goyal\(^b\), Jose Pichardo\(^a\), Joseph Mattana\(^a\)

\(^a\) Department of Medicine, St. Vincent’s Medical Center, Bridgeport, CT, The Frank H. Netter MD School of Medicine at Quinnipiac University, North Haven, CT, United States

\(^b\) Department of Radiology, St. Vincent’s Medical Center, Bridgeport, CT, The Frank H. Netter MD School of Medicine at Quinnipiac University, North Haven, CT, United States

**Article info**

Received 18 December 2018
Received in revised form 13 January 2019
Accepted 13 January 2019

Keywords:
Babesiosis
Splenic infarction

**Introduction**

An intraerythrocytic protozoon of genus Babesia causes human babesiosis, earlier known as “Nantucket fever”. The incidence of babesiosis is steadily increasing across the Northeast and upper Midwest United States [1]. Most infections are asymptomatic, although older and immunocompromised persons can develop severe and fatal disease. In addition, the clinical presentation can vary substantially posing diagnostic challenges for the clinician. Splenic infarction, a known complication with plasmodium infection, has only rarely been described with human babesiosis [2]. Here we describe a case of severe babesiosis leading to infarction of the spleen.

**Case report**

A 60-year-old man with hypertension, diabetes mellitus and hyperlipidemia presented to the emergency department with complaints of intermittent high-grade fever, chills and rigors for 7–10 days. He had seen a physician 4 days before the presentation and was treated with ciprofloxacin but he remained febrile and developed malaise, anorexia and diffuse abdominal pain. He denied nausea, vomiting, change in bowel habits, rash, chest pain, cough or dyspnea. He had moved to Connecticut, US, from India 8 months prior and denied any recent travel, exposure to pets or tick bites. The initial physical examination revealed fever (39.4 °C), tachycardia (heart rate 120/min), tachypnea (respiratory rate 24/min) and normal blood pressure. Icterus was noted and there was no thrush, oral ulcer, skin rash, joint swelling or cardiac murmur. The pulmonary, cardiovascular and abdominal examinations were unremarkable except for the above findings. Laboratory results included a total leukocyte count of 6300 cells/mm\(^3\), hemoglobin level of 10.2 g/dL, platelet count of 36,000/mm\(^3\), aspartate aminotransferase level of 124 U/L, alanine aminotransferase level of 65 U/L, alkaline phosphatase level of 126 U/L, total bilirubin 5.7 mg/dL and direct bilirubin of 1.6 mg/dL. HIV antibody was negative, urinalysis was negative for pyuria and two sets of blood cultures were negative for any growth. Electrocardiogram and chest radiographs were normal.

Due to his non-specific systemic symptoms and elevated aminotransferases, ultrasound and contrast enhanced CT scan of the abdomen were done which showed hepatosplenomegaly and features suggestive of acute splenic infarction (Fig. 1). The patient was admitted to the intensive care unit for further management.

The follow up laboratory studies revealed worsening anemia (hemoglobin 7.3 g/dL), an elevated reticulocyte count (corrected 4.8%) and lactate dehydrogenase (1443 U/L) and a negative direct Coombs test. Parasite smear showed intraerythrocytic ring forms suggestive of Babesia microti infection with a parasite load of 11% and was negative for Plasmodium. Treatment with azithromycin and atovaquone was started. Doxycycline therapy was added for possible co-infection with Borrelia species or Anaplasma species. On day 3 of hospitalization the patient developed left sided upper abdominal pain. Ultrasonography of the abdomen was done which showed a large, wedge shaped hypoechoic area in the mid-splenic area, along with multiple peripherally distributed hypoechoic areas most consistent with infarction. The spleen capsule was

https://doi.org/10.1016/j.idcr.2019.e00491

2214-2509/© 2019 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
intact and there was no free fluid. The Western blot tests for reactivity to Babesia microti were positive for both IgM (>1:320) and IgG (1:256). The Lyme serum enzyme immunoassay was positive but Western blot testing did not confirm infection. Western blot analysis for reactivity to Anaplasma phagocytophilum IgM and IgG were negative. Doxycycline was discontinued after confirmation of the absence of co-infection. The parasitemia improved gradually with disappearance of parasites from the blood smear on day 6. The patient improved symptomatically with normalization of liver function testing and he was discharged after 14 days of hospitalization with a hemoglobin level of 12.2 g/dL.

Discussion

Human babesiosis caused by hemoprotozoa of the genus Babesia is an emerging tick-borne infectious disease. Primarily recognized as pathogens affecting wild and domestic animals, over the last few decades it has been increasingly recognized as a cause of significant human disease. Though more than 100 species of Babesia are well known, most of the human infections in United States are caused by the parasite Babesia microti. In eastern North America, the primary reservoir for B. microti is the white-footed mouse and the primary tick vector of this species is I. scapularis. In endemic areas, up to two-thirds of these mice have been found to be parasitic with B. microti along with Borrelia burgdorferi and Anaplasma phagocytophilum. Ticks may subsequently become infected with these parasites during the blood meal. Human babesiosis is commonly caused by direct tick inoculation, although contaminated blood transfusion and rarely transplacental transmission have been reported [1,3].

Immunocompetent patients with babesiosis typically develop only low-level parasitemia and clinically manifest with nonspecific flu-like symptoms, which may resolve spontaneously over a few weeks. However, patients with HIV infection, advanced age, asplenia, splenomegaly or other factors associated with immunosuppression are at high mortality risk [4,5]. The first human case of babesiosis was identified in an asplenic person who died of renal failure during the second week of illness, emphasizing the importance of a healthy spleen to fight the infection [6]. It is well known that the host immune response is required to clear
parasite infected red blood cells. In animal models IFN-γ in synergy with TNF-α activates macrophages to produce nitric oxide and kill the parasite [7,8]. The effects of these inflammatory mediators are countered by anti-inflammatory cytokines, mainly IL-4 and IL-10, which help to restrict the inflammatory process to the spleen and prevent systemic overflow (Fig. 1).

Severe parasitemia is associated with a stronger inflammatory reaction that can damage the spleen in part by interrupting the microcirculation, potentially manifesting as splenic infarction. This mechanism may account for splenic infarction seen in high parasitemia states such as in our patient, although there are reports of splenic infarction occurring in low parasitemia states as well [2]. In such circumstances a proposed mechanism may be red cell lysis leading to formation of microthrombi. It should also be noted that subclinical splenomegaly due to splenic erythropoietic cytosis has been found in many cases. In a Syrian hamster animal model B. microti infection caused multifocal coagulative necrosis of the spleen [9]. In some case reports, autopsy revealed the parasite within the spleen, although there was no evidence of thrombosed or embolized splenic vessels [8]. With the increasing incidence of babesiosis infection the incidence of splenic infarction or rupture may be expected to increase as well. The prognosis of cases complicated by splenic infarction remains uncertain and it is unclear whether more extensive inflammatory or non-functionality of the spleen is associated with worse outcomes, though mortality up to 42% has been reported in asplenic patients [10].

Treatment of babesiosis remains challenging. Current guidelines recommend combination therapy, which could be azithromycin and atovaquone for mild infection or clindamycin and quinine for severe infection for total of 7–10 days. There is still debate regarding the best regimen for severe infection though azithromycin and atovaquone may be better tolerated and more efficacious [11–13]. Plasmapheresis is another potential option for persistent high-grade parasitemia (>10%) with significant hemolysis, or renal, hepatic, or pulmonary compromise [14]. In immunosuppressed patients with independent risk factors for a poor prognosis such as asplenia, HIV and cytopenia there is a significant risk for delayed parasitic clearance and relapse [5]. In these circumstances a prolonged treatment course and monitoring for parasitic clearance using PCR-based testing may be warranted [15].

While it is possible that there was another etiology for our patient’s splenic infarction, he had no evidence of an immunocompromised state or conditions such as endocarditis, vascular disease or malignancy, which could account for his developing splenic infarction. Moreover, the patient’s symptoms improved quickly and parasitemia cleared after starting appropriate treatment, suggesting babesiosis was the likely etiology.

Conclusion

Our case illustrates that babesiosis should be considered in the differential diagnosis of patients presenting with non-specific symptoms and splenic infarction, particularly in endemic areas, as prompt and early treatment is crucial to prevent life-threatening complications such as spontaneous splenic rupture. Of note, our case also illustrates that, in contrast to other complications of babesiosis, splenic infarction can occur despite the lack of an immunocompromised state. While often under-recognized, early recognition and treatment of babesiosis can greatly reduce morbidity and mortality.

Conflict of interest

There is no conflict of interest.

Funding

No source of funding.

Consent

Patient’s consent was obtained for the publication.

References

[1] Vannier E, Krause PJ. Human babesiosis. N Engl J Med 2012; 366(25):2397–407.
[2] Florescu D, Sordillo PP, Glyptis A, Zlatanic E, Smith B, Polsky B, et al. Splenic infection in human babesiosis: two cases and discussion. Clin Infect Dis 2008;46(1):e9–11.
[3] Ord RL, Lobo GA. Human babesiosis: pathogens, prevalence, diagnosis, and treatment. Curr Clin Microbiol Rep 2015;2(4):173–81.
[4] Hatcher JC, Greenberg PD, Antique J, Jimenez-Lucho VE. Severe babesiosis in Long Island: review of 34 cases and their complications. Clin Infect Dis 2001;32(8):1117–25.
[5] Krause PJ, Gewurz BE, Hill D, Marty FM, Vannier E, Foppa IM, et al. Persistent and relapsing babesiosis in immunocompromised patients. Clin Infect Dis 2008;46(3):370–6.
[6] Skrabało Z, Deanovic Z. Piroplasmosis in man: report of a case. Doc Med Geogr Trop 1957;9(1):11–6.
[7] Chen D, Copeman DB, Burnett J, Hutchinson GW, Helper T cell and antibody responses to infection of CBA mice with Babesia microti. Parasite Immunol 2000;22(2):81–8.
[8] Goff WL, Johnson WC, Tuo W, Valdez RA, Parish SM, Barrington GM, et al. Age-related innate immune response in calves to Babesia bovis involves IL-12 induction and IL-10 modulation. Ann NY Acad Sci 2002;969:164–8.
[9] Hu R, Yeh MT, Hyland KE, Mather TN. Experimental Babesia microti infection in golden hamsters: immunoglobulin G response and recovery from severe hemolytic anemia. J Parasitol 1996;728–32.
[10] Hunfeld KP, Hildebrandt A, Gray JS. Babesiosis: recent insights into an ancient disease. Int J Parasitol 2008;38(11):1219–37.
[11] Wormser GP, Dattwyler RJ, Shapiro ED, Halperin JJ, Steere AC, Klemperer MS, et al. The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006;43(9):1089–134.
[12] Weiss LM. Babesiosis in humans: a treatment review. Expert Opin Pharmacother 2002;3(8):1109–15.
[13] Krause PJ, Lepore T, Sikand Jr. VK, Gadbach J, Burke G, Telford SR, et al. Atovaquone and azithromycin for the treatment of babesiosis. N Engl J Med 2000;343(20):1454–8.
[14] Saitoe NH, Krause PJ, Wu Y. Apheresis for babesiosis: therapeutic parasite reduction or removal of harmful toxins or both? Clin Apher 2016;31(5):454–8.
[15] Vannier E, Krause PJ. Update on babesiosis. Interdiscip Perspect Infect Dis 2009;2009;